The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
The substantia nigra of the human brain
Abstract
To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Estimation of nuclear population from microtome sections
Abercrombie, M. (1946) · The Anatomical Record · doi:10.1002/ar.1090940210 · Cited by 4,363
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 3×
“These observations confirm the earlier reports (Hirsch et al., 1988; Germanet al., 1989).”
BackgroundInfluentialSelf-citationBrooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
Self-citationMidbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340331 · Cited by 320
Cited by
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
“Damage to specific subnuclei of the substantia nigra, pars compacta, with severe obliteration of their neuromelaninladen projection neurons, frequently is considered to be the most important hallmark of PD [ 20 ,31,38,39,43].”
BackgroundResultDauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Bioinspired catecholic chemistry for surface modification
Ye, Q., Zhou, F., & Liu, W. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15026j · Cited by 1,177
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
von Bartheld, C. S., Bahney, J., & Herculano‐Houzel, S. (2016) · Journal of Comparative Neurology · doi:10.1002/cne.24040 · Cited by 1,063
“The Journal of Comparative Neurology | Research in Systems Neuroscience 3881 classical studies documenting the loss of neurons in degenerative diseases, for example correlating the extent of neuron loss with disease severity (Damier et al., 1999; Stark and Pakkenberg, 2004; Kordower et al., 2013).”
BackgroundSelective neuronal vulnerability to oxidative stress in the brain
Wang (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00012 · Cited by 1,008
Metal nanoclusters: novel probes for diagnostic and therapeutic applications
Tao, Y., Li, M., Ren, J., & Qu, X. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00607d · Cited by 736
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citationHartmann, A., Hunot, S., Michel, P. P., Muriel, M.-P., Vyas, S., Faucheux, B. A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 715
Self-citationGao, H., Jiang, J., Wilson, B., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 687
Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.013 · Cited by 682
Neuropathology of Parkinson disease
Dickson, D. W. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.033 · Cited by 623
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Self-citationMultiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
A Review of Organic and Inorganic Biomaterials for Neural Interfaces
Fattahi, P., Yang, G., Kim, G., & Abidian, M. R. (2014) · Advanced Materials · doi:10.1002/adma.201304496 · Cited by 580
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
Self-citationKamath, T., Abdulraouf, A., Burris, S. J., Langlieb, J., Gazestani, V., Nadaf, N. M., Balderrama, K., Vanderburg, C., & Macosko, E. Z. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01061-1 · Cited by 552
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments
Crittenden, J. R., & Graybiel, A. M. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00059 · Cited by 481
Self-citationSignaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3039 · Cited by 449
Akkal, D., Dum, R. P., & Strick, P. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3134-07.2007 · Cited by 442
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Ping, J., Wu, J., Wang, Y., & Ying, Y. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.01.016 · Cited by 425
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis
Yan, C., Gong, L., Chen, L., Xu, M., Abou-Hamdan, H., Tang, M., Désaubry, L., & Song, Z. (2020) · Autophagy · doi:10.1080/15548627.2019.1628520 · Cited by 413
Fu, Y.-S., Cheng, Y.-C., Lin, M.-Y. A., Cheng, H., Chu, P.-M., Chou, S.-C., Shih, Y.-H., Ko, M.-H., & Sung, M.-S. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0053 · Cited by 409
Liu, C., Wang, K., Luo, S., Tang, Y., & Chen, L. (2011) · Small · doi:10.1002/smll.201002340 · Cited by 405
Resting state functional connectivity of the striatum in Parkinson’s disease
Hacker, C. D., Perlmutter, J. S., Criswell, S. R., Ances, B. M., & Snyder, A. Z. (2012) · Brain · doi:10.1093/brain/aws281 · Cited by 404
Pitx3 is required for development of substantia nigra dopaminergic neurons
Nunes, I., Tovmasian, L. T., Silva, R. M., Burke, R. E., & Goff, S. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230529100 · Cited by 385
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
The MPTP model of Parkinson's disease
Smeyne, R. J., & Jackson-Lewis, V. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.017 · Cited by 377
Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling
Poulin, J.-F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y. A., Cicchetti, F., & Awatramani, R. B. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.008 · Cited by 352
FEDOROW, H., TRIBL, F., HALLIDAY, G., GERLACH, M., RIEDERER, P., & DOUBLE, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.001 · Cited by 350
Jellinger, K. A. (1999) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6360-3_1 · Cited by 347
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Overview of quantitative susceptibility mapping
Deistung, A., Schweser, F., & Reichenbach, J. R. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3569 · Cited by 338
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
Schwarz, S. T., Afzal, M., Morgan, P. S., Bajaj, N., Gowland, P. A., & Auer, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093814 · Cited by 330
Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling
Nichterwitz, S., Chen, G., Aguila Benitez, J., Yilmaz, M., Storvall, H., Cao, M., Sandberg, R., Deng, Q., & Hedlund, E. (2016) · Nature Communications · doi:10.1038/ncomms12139 · Cited by 325
Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass
Menegas, W., Bergan, J. F., Ogawa, S. K., Isogai, Y., Umadevi Venkataraju, K., Osten, P., Uchida, N., & Watabe-Uchida, M. (2015) · eLife · doi:10.7554/elife.10032 · Cited by 322
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Baquet, Z. C., Bickford, P. C., & Jones, K. R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4601-04.2005 · Cited by 307
Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration
Kaplan, A., Spiller, K. J., Towne, C., Kanning, K. C., Choe, G. T., Geber, A., Akay, T., Aebischer, P., & Henderson, C. E. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.009 · Cited by 306
Mitochondrial Biology and Parkinson's Disease
Perier, C., & Vila, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009332 · Cited by 306
Cell-based therapies for Parkinson disease—past insights and future potential
Barker, R. A., Drouin-Ouellet, J., & Parmar, M. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.123 · Cited by 306
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons
Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., & Roeper, J. (2005) · Nature Neuroscience · doi:10.1038/nn1570 · Cited by 299
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?
Lawrence, A. D., Evans, A. H., & Lees, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00529-5 · Cited by 282
A dual fluorometric and colorimetric sensor for dopamine based on BSA-stabilized Aunanoclusters
Tao, Y., Lin, Y., Ren, J., & Qu, X. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.10.014 · Cited by 281
Hardman, C. D., Henderson, J. M., Finkelstein, D. I., Horne, M. K., Paxinos, G., & Halliday, G. M. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10165 · Cited by 280
Giasson, B. I., Ischiropoulos, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 279
Crocker, S. J., Smith, P. D., Jackson-Lewis, V., Lamba, W. R., Hayley, S. P., Grimm, E., Callaghan, S. M., Slack, R. S., Melloni, E., Przedborski, S., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-10-04081.2003 · Cited by 274
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Stem cell technology for neurodegenerative diseases
Lunn, J. S., Sakowski, S. A., Hur, J., & Feldman, E. L. (2011) · Annals of Neurology · doi:10.1002/ana.22487 · Cited by 272
Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7 T MRI
Blazejewska, A. I., Schwarz, S. T., Pitiot, A., Stephenson, M. C., Lowe, J., Bajaj, N., Bowtell, R. W., Auer, D. P., & Gowland, P. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829e6fd2 · Cited by 269
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function
Hao, L.-Y., Giasson, B. I., & Bonini, N. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911175107 · Cited by 263
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
Ross, G. W., Petrovitch, H., Abbott, R. D., Nelson, J., Markesbery, W., Davis, D., Hardman, J., Launer, L., Masaki, K., Tanner, C. M., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20226 · Cited by 260
Aging of cerebral white matter
Liu, H., Yang, Y., Xia, Y., Zhu, W., Leak, R. K., Wei, Z., Wang, J., & Hu, X. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.006 · Cited by 260
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease
Piccini, P., Pavese, N., Hagell, P., Reimer, J., Björklund, A., Oertel, W. H., Quinn, N. P., Brooks, D. J., & Lindvall, O. (2005) · Brain · doi:10.1093/brain/awh649 · Cited by 254
Iravani, M. M., Kashefi, K., Mander, P., Rose, S., & Jenner, P. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00562-0 · Cited by 247
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
Self-citationBurn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.17 · Cited by 203
Lewis, S. J. G., Cools, R., Robbins, T. W., Dove, A., Barker, R. A., & Owen, A. M. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(02)00257-9 · Cited by 201
Role of the Basal Ganglia in Category Learning: How Do Patients With Parkinson's Disease Learn?
Shohamy, D., Myers, C. E., Onlaor, S., & Gluck, M. A. (2004) · Behavioral Neuroscience · doi:10.1037/0735-7044.118.4.676 · Cited by 186
“However, as the disease progresses, there are changes in the degree and topography of dopamine cell loss: Later in the disease, damage progresses from the putamen and the dorsal caudate nucleus to more ventral parts of the striatum, and beyond the basal ganglia to the mesocorticolimbic dopamine system (Agid et al., 19…”
BackgroundNeuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Collier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R. A. E., Sladek, J. R., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.013 · Cited by 162
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., Rudenko, I., Zheng, W., Sastry, N., Luo, J., Rudow, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72176 · Cited by 166
“However, it is unclear whether the loss of DA neurons occurs randomly in the SNpc of mutant mice or shows any regional preference, as observed in the PD cases (2–4).”
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Panman, L., Papathanou, M., Laguna, A., Oosterveen, T., Volakakis, N., Acampora, D., Kurtsdotter, I., Yoshitake, T., Kehr, J., Joodmardi, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.016 · Cited by 143
“Notably, cells within the SNc are the most vulnerable mDA neurons and are severely affected in Parkinson’s disease (Damier et al., 1999; Fearnley and Lees, 1991).”
BackgroundIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Development, wiring and function of dopamine neuron subtypes
Garritsen, O., van Battum, E. Y., Grossouw, L. M., & Pasterkamp, R. J. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00669-3 · Cited by 128
Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools
Joksimovic, M., Anderegg, A., Roy, A., Campochiaro, L., Yun, B., Kittappa, R., McKay, R., & Awatramani, R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904285106 · Cited by 121
Identification of neurodegenerative factors using translatome–regulatory network analysis
Brichta, L., Shin, W., Jackson-Lewis, V., Blesa, J., Yap, E.-L., Walker, Z., Zhang, J., Roussarie, J.-P., Alvarez, M. J., Califano, A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4070 · Cited by 118
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson’s disease
Simon, D. K., Lin, M. T., Zheng, L., Liu, G.-J., Ahn, C. H., Kim, L. M., Mauck, W. M., Twu, F., Beal, M. F., & Johns, D. R. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00037-x · Cited by 118
“In advanced PD, as many as 98% of dopaminergic neurons can be lost in the most susceptible regions of the SN [15].”
BackgroundPathogenic Mechanisms of Neurodegeneration in Parkinson Disease
Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108
Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons
Steinkellner, T., Zell, V., Farino, Z. J., Sonders, M. S., Villeneuve, M., Freyberg, R. J., Przedborski, S., Lu, W., Freyberg, Z., & Hnasko, T. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95795 · Cited by 102
Kim, J.-H., Choi, D.-J., Jeong, H.-K., Kim, J., Kim, D. W., Choi, S. Y., Park, S.-M., Suh, Y. H., Jou, I., & Joe, E.-H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.007 · Cited by 102
“Parkinson's disease (PD), the second-most common progressive neurodegenerative movement disorder, is caused by the selective loss of dopaminergic neurons in the substantia nigra pars compacta (Baba et al., 1998; Damier et al., 1999).”
BackgroundOssowska, K., Śmiałowska, M., Kuter, K., Wierońska, J., Zięba, B., Wardas, J., Nowak, P., Dąbrowska, J., Bortel, A., Biedka, I., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.039 · Cited by 84
Calcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
Kramer, D. J., Risso, D., Kosillo, P., Ngai, J., & Bateup, H. S. (2018) · eNeuro · doi:10.1523/eneuro.0152-18.2018 · Cited by 70
Metadata
- Authors
- Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-08
- Volume
- 122
- Issue
- 8
- Pages
- 1437-1448
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1974898145
- Cited by
- 1,756
- References
- 13
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.